Marshall Wace LLP Acquires 2,732,546 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)

Marshall Wace LLP raised its stake in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 1,283.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,945,408 shares of the company's stock after buying an additional 2,732,546 shares during the quarter. Marshall Wace LLP owned 3.15% of Scholar Rock worth $127,301,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. GAMMA Investing LLC grew its holdings in shares of Scholar Rock by 51.8% during the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company's stock worth $34,000 after purchasing an additional 269 shares during the last quarter. Global Retirement Partners LLC raised its position in Scholar Rock by 584.7% during the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock worth $39,000 after acquiring an additional 766 shares in the last quarter. Nisa Investment Advisors LLC lifted its holdings in Scholar Rock by 1,321.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock worth $48,000 after purchasing an additional 1,031 shares during the last quarter. Amalgamated Bank raised its stake in Scholar Rock by 30.6% in the fourth quarter. Amalgamated Bank now owns 2,643 shares of the company's stock valued at $114,000 after purchasing an additional 620 shares in the last quarter. Finally, KBC Group NV bought a new position in Scholar Rock in the 4th quarter valued at approximately $131,000. Institutional investors and hedge funds own 91.08% of the company's stock.

Scholar Rock Price Performance

Shares of NASDAQ SRRK traded up $0.14 during trading on Monday, hitting $30.89. The company had a trading volume of 296,856 shares, compared to its average volume of 1,233,478. The stock has a fifty day simple moving average of $33.26 and a two-hundred day simple moving average of $35.47. The firm has a market capitalization of $2.93 billion, a price-to-earnings ratio of -13.14 and a beta of 0.56. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock Holding Co. has a fifty-two week low of $6.76 and a fifty-two week high of $46.98.

Insider Transactions at Scholar Rock

In other news, CFO Edward H. Myles sold 7,809 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $36.83, for a total transaction of $287,605.47. Following the sale, the chief financial officer now owns 140,740 shares of the company's stock, valued at $5,183,454.20. The trade was a 5.26 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jay T. Backstrom sold 18,372 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $36.83, for a total value of $676,640.76. Following the completion of the transaction, the chief executive officer now owns 311,991 shares of the company's stock, valued at $11,490,628.53. The trade was a 5.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 250,231 shares of company stock valued at $9,056,086. 19.20% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Separately, Wedbush restated an "outperform" rating and issued a $50.00 target price on shares of Scholar Rock in a report on Tuesday, March 25th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Scholar Rock presently has an average rating of "Buy" and an average price target of $42.67.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.